Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis

BACKGROUND: Preterm infants born between 33 and 35 weeks of gestational age (wGA) have been considered a “major underserved population” and ineligible to receive palivizumab (PLV), the only drug authorized to date for respiratory syncytial virus (RSV) prophylaxis, by current international guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondì, Vito, Paolillo, Piermichele, Bedetta, Manuela, Lucangeli, Natalia, Picone, Simonetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285389/
https://www.ncbi.nlm.nih.gov/pubmed/37360357
http://dx.doi.org/10.3389/fped.2023.1154518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285389/
https://www.ncbi.nlm.nih.gov/pubmed/37360357
http://dx.doi.org/10.3389/fped.2023.1154518

Ejemplares similares